News >

Immunotherapy/Chemo Combinations Show Continued Benefit in NSCLC

Caroline Seymour
Published: Thursday, Jan 17, 2019

Vinay Gupta, MD

Vinay Gupta, MD

Several clinical trials have evaluated the addition of immunotherapy to standard chemotherapy in the frontline treatment of patients with advanced non–small cell lung cancer (NSCLC), explained Vinay Gupta, MD, all of which echo similar conclusions: these combinations are a mainstay in this population.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication